BGI Genomics Co

BGI Genomics Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of BGI Genomics Co (300676.SZ) as of Oct 29, 2026 is -119.61. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -23.24 — a change of 414.66% (lower).

EV/EBIT

-119.61

YoY

414.66%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of BGI Genomics Co is 2025 -119.61 . EV/EBIT (Enterprise Value to EBIT) of BGI Genomics Co was 2024 -23.24 . It decreases by 414.66% lower compared to the previous year.

The BGI Genomics Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
61.58 CNY
Jan 1, 2020
8.14 CNY
Jan 1, 2021
11.15 CNY
Jan 1, 2022
18.69 CNY
Jan 1, 2023
134.95 CNY
Jan 1, 2024
-23.24 CNY
Jan 1, 2025
-119.61 CNY
Jan 1, 2026 (e)
87.45 CNY
The BGI Genomics Co EV/EBIT history
YEAREV/EBITYoY
est87.45-173.11%
-119.61+414.66%
-23.24-117.22%
134.95+622.15%
18.69+67.55%
11.15+37.05%
8.14-86.79%
61.58+44.92%
42.50+5.38%
40.33-43.19%
70.98+6.11%
66.90-82.38%
379.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BGI Genomics Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides BGI Genomics Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates BGI Genomics Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots BGI Genomics Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if BGI Genomics Co grows earnings faster than its peers.

BGI Genomics Co Stock analysis

What does BGI Genomics Co do? BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities. BGI Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BGI Genomics Co stock

EV/EBIT (Enterprise Value to EBIT) of BGI Genomics Co is -119.61 in 2025.

EV/EBIT (Enterprise Value to EBIT) of BGI Genomics Co changed from -23.24 to -119.61, representing a 414.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) BGI Genomics Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s BGI Genomics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — BGI Genomics Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — BGI Genomics Co